Introduction
The number of people living with HIV worldwide continues to grow (36.7 million in 2015) [1] and HIV-infected individuals are living longer due to advances in combined anti-retroviral therapy (cART) [2] . As a result, the number of patients with HIV requiring treatment for malignancy is increasing. Mortality from non-AIDSdefining cancers (NADCs) is rising and the incidence of AIDS-defining cancers (ADCs) is still greater in HIV patients on cART than in the general population [2] .
Undesirable drug-drug interactions (DDIs) and toxicities remain among the biggest challenges in HIV management. The coadministration of cART and chemotherapy is particularly complex because of the narrow therapeutic index of anticancer agents and [17] including numerous anti-neoplastic drugs and ARVs [3] . CYP3A4 plays a role in the metabolism of all PIs, NNRTIs, the newer INSTIs elvitegravir and dolutegravir and maraviroc [3, [18] [19] [20] .
CYP450 inhibition by other drugs or dietary substances, of which grapefruit juice is a well-known example, reduces elimination of the affected drug. This results in a higher concentration of the affected drug and a reduced concentration of its metabolites [3, 17] . The potent CYP450 inhibitors ritonavir and cobicistat are used therapeutically in cART to 'boost' the drug levels of PIs and the INSTI elvitegravir [18] .
The NNRTIs nevirapine and efavirenz are both substrates and inducers of CYP3A4 and, therefore, potential 'victims' as well as 'perpetrators' of DDIs. CYP450 induction by nevirapine and efavirenz results in increased clearance of anti-cancer drugs metabolized by CYP450, e.g. taxanes, vinca alkaloids, etoposide and erlotinib. Conversely, PIs inhibit CYP450 and can result in severe toxicity of these drugs [10, 21, 22] .
Inhibitors of tyrosine kinase and mTOR are also substrates as well as inducers/inhibitors of CYP450 and may be involved in bidirectional DDIs with cART [4, 23] . Anthracyclines, antimetabolites, antitumor antibiotics, and platinums undergo non-CYP450 routes of elimination and are not susceptible to CYP450 drug interactions [4] . Monoclonal antibodies (mAb) are metabolized into small peptides and are not known to have a direct effect on the metabolic pathways of other drugs [3] .
UDP-Glucuronosyltransferase 1 UDP-glucuronosyltransferase 1 (UGT-1A) transforms small lipophilic molecules, including bilirubin, hormones and drugs, into water-soluble, excretable metabolites through glucoronidation [24] . UGT-1A metabolizes several ARVs (including PIs and maraviroc) and anti-neoplastic drugs (e.g. irinotecan and etoposide) with further potential for DDIs [3] . The INSTI raltegravir is the only ARV metabolized exclusively by UGT-1A and has very few DDIs with anti-cancer drugs [3, 25, 26] .
P-Glycoprotein Efflux Pump
Permeability glycoprotein 1 (P-gp) is also known as multidrug resistance protein 1 (MDR1) or ABCB1. It is an important protein of the cell membrane that plays a vital role in the absorption and cellular transport of PIs and the metabolism of several cytotoxics, including vinca alkaloids, taxanes, doxorubicin and etoposide [27] . In addition to inhibiting CYP450, the PIs also inhibit P-gp. Co-administration with PIs therefore cause higher intracellular concentrations of these drugs [3] .
Due to the above pharmacokinetic mechanisms, there is a high risk of bidirectional DDIs between cART and alkylating agents, epipodophyllotoxins, taxanes, tyrosine kinase inhibitors, vinca alkaloids and corticosteroids [4, 28] . These interactions are highly unpredictable. For example, erlotinib exposure in human hepatocytes increased 4.2-fold when co-administered with ritonavir and decreased 3-fold with efavirenz [23] . On the other hand, docetaxel exposure in mice increased 6.9-fold with ritonavir co-administration, but was unaffected by efavirenz [29] .
Genetic Factors
To add to the complexity, expression of CYP450, UDP-G1 and P-gp is determined by numerous genetic polymorphisms. Significant inter-ethnic variation in drug metabolism (e.g. NNRTIs) and toxicity (e.g. irinotecan-associated neutropenia) make interactions even more unpredictable [17, 27, 30] . To date, 52 FDA-approved anti-cancer drugs including cisplatin, irinotecan and mycophenolate contain pharmacogenetic information in their labelling, which may improve therapeutic efficacy and pre-identify patients at risk for toxicities [31] .
cART in HIV Patients with Malignant Disease
When to Start Numerous reports have found the concurrent treatment of malignant disease and HIV to be safe and to result in improved outcomes [32] [33] [34] . A meta-analysis by Barta et al. [35] of 19 phase II and III studies completed between 2000 and 2011 found that cART combined with chemotherapy for non-Hodgkin lymphomas (NHLs) was associated with higher rates of complete response (CR) and a trend towards increased overall survival (OS). Even for patients with NADCs, e.g. non-small cell lung cancer, the absence of cART was an independent predictor of poor response to chemotherapy [34] .
No specific guidelines are available on when to start cART for patients with malignancy. Earlier concerns that drug interactions between cART and chemotherapy invariably result in more complications are unjustified since the advent of newer ARVs. Most international guidelines recommend continuing cART in HIV patients already on therapy during cancer treatment [36, 37] . For patients not yet on cART, usually those in whom the malignancy and HIV are diagnosed simultaneously, cART should be started in parallel to chemotherapy [36, 37] . Since the newer ARVs are associated with few unwanted side effects, it is feasible to start cART and monitor for early side effects in the few weeks that it usually takes for staging and planning of cancer treatment. If this is not possible due to the urgency of starting chemotherapy, it is acceptable to wait until the patient is stable from an oncological point of view, e.g. after the first cycle of chemotherapy for HIV-related lymphoma [36] . This recommendation is based not on controlled trials but on case reports and -series. There is an even greater paucity of data for NADCs, e.g. acute leukemias [38, 39] .
International HIV treatment guidelines now recommend starting cART at HIV diagnosis regardless of CD4 cell count. The lower the CD4 count, the greater the urgency to start cART [14, 16, 40] . The British guidelines, for example, recommend starting cART within 2 weeks of initiating specific antimicrobial chemotherapy in patients with an AIDS-defining infection and a CD4 cell count of < 200 cells/μl [14] . In the absence of specific guidelines for malignancy, this underlines the fact that cART improves outcomes and should be started without delay even in seriously ill patients in whom complex DDIs and toxicities can be anticipated.
Patients with antibodies against hepatitis B core antigen (HBcAb) who require anti-viral prophylaxis to prevent HBV reactivation due to chemotherapy or rituximab, should be started on cART prior to chemotherapy since HBV prophylaxis with lamivudine or tenofovir monotherapy without cART is likely to lead to the development of HIV drug-resistance [36, 41] .
Which Anti-Retroviral Drugs
There have been no controlled trials to identify the optimal cART in combination with cancer chemotherapy. Based on pharmacokinetics, ARVs that are metabolized independently of the CYP450 pathway (e.g. NRTIs, raltegravir and enfuvirtide) or that are substrates of CYP450 but do not activate or inhibit it (e.g. rilpivirine) are preferred [3] .
Nucleoside Reverse Transcriptase Inhibitors
NRTIs have only minimal effect on the CYP450 system and are not involved in DDIs. Standard criteria for cART choice including HIV resistance, renal function for tenofovir and HLA B5701 positivity for abacavir apply [14] [15] [16] .
The NRTI tenofovir disoproxil fumarate (TDF), a prodrug of the active anti-viral tenofovir (TFV), has previously been recommended for use with chemotherapy [36] . TDF is mainly renally eliminated. Co-administration with anti-cancer drugs (e.g. cisplatin) that reduce renal function or compete for active tubular secretion may increase serum concentrations of TDF and of other renally eliminated drugs. The combination of TDF and cisplatin is, therefore, potentially nephrotoxic [42] .
A new NRTI, tenofovir alanefanimide (TAF) is a more efficient prodrug of TFV with an improved side-effect profile. TAF produces higher levels of intracellular TFV in HIV-infected target cells at much lower oral doses of TFV equivalent. This allows effective HIV therapy with 90% lower systemic exposure to TFV, thereby reducing renal and bone toxicity [43] . Patients with mild to moderate renal impairment on TDF who were switched to TAF showed significant improvements in proteinuria, albuminuria and tubular proteinuria [44] . This suggests that overlapping renal toxicity with chemotherapy is less likely with TAF than with TDF, and that TAF is theoretically preferable in patients receiving chemotherapy. A potential disadvantage of TAF, is the possibility of DDIs. TAF is transported by P-gp and drugs that strongly affect P-gp activity may cause changes in its absorption. Inhibitors of P-gp, e.g. ritonavir, cobicistat, cyclosporine, and itraconazole, increase the plasma concentration of TAF and a lower dose is required. TAF is therefore dosed (10 mg or 25 mg) according to the presence or absence of such drugs [43] .Based on the above, the use of chemotherapy with the most commonly prescribed singletablet NRTI combinations (TDF with emtricitabine, TAF with emtricitabine or abacavir with lamivudine) is relatively uncomplicated.
Several older NRTIs such as didanosine and D4T should no longer be used due to unacceptable side effects including hepatotoxicity and polyneuropathy. Zidovudine (AZT) is associated with mitochondrial toxicity and myelotoxicity and is now rarely used in Europe and North America [14] [15] [16] . Should the use of AZT with chemotherapy be unavoidable, e.g. due to drug resistance, careful management of hematological toxicity is essential.
Integrase Inhibitors
Raltegravir has no effect on CYP450 and, therefore, no CYP450-mediated DDIs with chemotherapy agents. It is a substrate of UGT-1A but does not induce or inhibit it. Although irinitecan, for example, is also partly metabolized by UGT-1A, no interactions are anticipated [25] . Raltegravir plus 2 NRTIs is therefore the cART of choice in patients requiring chemotherapy where the HIV treatment history and resistance profile allow. This recommendation is based on cohort data, meta-analyses, case reports and pharmacokinetic considerations [25, 26, 45, 46] [18] . Dolutegravir is metabolized mainly by UGT-1A with a minor contribution by CYP3A4 [19] . The theoretical risk of DDIs is small but there is currently little published experience of its use with anti-cancer agents and raltegravir is preferred.
HIV Protease Inhibitors
The largest study to date comparing different cART combinations in HIV-infected patients with cancer found PI-based regimens to be the least favorable [11] . Non-hematological side effects occurred in 35% of patients receiving PIs versus 14% on NNRTIs and 3% on INSTIs [11] .
In another study of patients with AIDS-related NHL treated with cART and cyclophosphamide, doxorubicin and etoposide, grade 3-4 infections requiring hospitalization were significantly more common in cycles on a PI (48%) than on PI-sparing cART (25%). Grade 4 neutropenia occurred in 54% of cycles on a PI compared to 38% on PI-sparing cART. However, there was no difference in CR, disease-free survival or OS between the 2 groups [12] .
Severe neurotoxicity due to vinblastine [7] and life-threatening toxicity with paclitaxel [13] have been reported in combination with boosted PIs. PIs may also increase concentrations of erlotinib and geftonib causing serious toxicity, including severe skin reactions and interstitial lung disease [21] . PIs are therefore best avoided in combination with anti-cancer drugs unless the patient has no other ARV options.
Non-Nucleoside Reverse Transcriptase Inhibitors
As with nevirapine and efavirenz, the newer NNRTI etravirine is a moderate inducer of CYP3A4 and is not recommended with anti-cancer drugs. Rilpivirine is only a substrate of CYP3A and should theoretically not affect anti-neoplastic drug levels. However, CYP450 inducers, e.g. dexamethasone, reduce rilpivirine levels risking failure of HIV suppression and should be avoided [47] .
Maraviroc and Enfuvirtide
Maraviroc does not induce or inhibit CYP3A4, and is not expected to affect anti-neoplastic drug concentrations. However, it is metabolized by CYP3A4 and P-gp and is therefore a potential 'victim' of many DDIs [20] .
Enfuvirtide undergoes hydrolysis and no drug interactions have been reported. Its use is limited by the need for twice daily subcutaneous injections and injection site reactions [48] . It may be a temporary option when no alternative ARVs are feasible during chemotherapy.
Avoiding and Managing DDIs
The decision whether to start or modify cART prior to chemotherapy should involve an oncologist, an infectious diseases physician and a clinical pharmacologist.
Factors to consider include: -The degree of immune suppression (absolute CD4 cell count and CD4 percentage), which can be expected to worsen during chemotherapy [32, 49] . Patients with CD4 cell counts of < 200 cells/μl and/or a CD4 percentage of < 14% are at increased risk of serious opportunistic infections and death [40] . -cART options and the feasibility of using a cART that is free of DDIs and overlapping toxicities with the proposed anti-cancer drugs. -The benefit of HIV viral suppression for tumor response and survival. Prior to starting chemotherapy in patients on cART or vice versa, it is essential to check the pathways of metabolism and potential DDIs between each ARV, proposed chemotherapy agent and all other medications. Several online tools, such as www.hivdruginteractions.org, exist to aid decision making [4, 50] . If a potential DDI is predicted, options include: -Choosing another ARV if possible -Chemotherapy dose reduction -Choosing an alternative chemotherapy regimen -Therapeutic drug monitoring (TDM) or pharmacogenetic analysis where available. Where a PI is essential, e.g. due to drug resistance, dose reduction of, among others, taxanes should be considered [13] . TDM is being validated for progressively more anti-cancer drugs [51] , and may increasingly help to simplify the management of DDIs by improving efficacy and reducing toxicity.
Avoiding Overlapping Toxicities
Numerous drugs without DDIs share side effects with ARVs that are worsened by their co-administration. For example, pemetrexed renal toxicity overlaps with tenofovir and its hematological toxicity with zidovudine [21] . Most PIs as well as rilpivirine and efavirenz can cause QT-interval prolongation [52] . Many anti-cancer agents including anthracyclines, tamoxifen, tyrosine kinase inhibitors and arsenic trioxide may also prolong the QT interval [53] . Co-administration of ARVs with these drugs risks ventricular arrhythmias and sudden death. It should be avoided wherever possible or otherwise closely monitored.
Maintaining HIV Viral Suppression
Although very few chemotherapy agents interfere with the plasma or intracellular concentration of ART, factors associated with HIV treatment failure are common in cancer patients. These include co-morbidities, drug side effects, trouble in swallowing pills, depression and variable absorption, e.g. from persistent vomiting [4] . In 1 study that looked at the effect of chemotherapy on cART, 3 of 19 patients (16%) receiving CHOP for NHL, and 6 of 19 (32%) receiving rituximab-CDE developed virological failure during chemotherapy [54] . HIV viral load and cART adherence are easily overlooked during oncology visits and should be regularly monitored.
For patients with difficulty in swallowing pills, e.g. due to a severe mucositis, ARV tablets can be crushed (e.g. abacavir, emtricitabine, lamivudine, AZT, darunavir, nevirapine) or given as liquid formulations (atazanavir powder, lopinavir/ritonavir syrup or raltegravir granules) or injectables (enfuvirtide or intravenous AZT) [55] .
Use of Supportive Therapy

Prophylaxis and Treatment of Opportunistic Infections
Prophylaxis for Pneumocystis jirovecii pneumonia or Mycobacterium avium-intracellulare should be started before cancer therapy in patients with CD4 cell counts just above 200 cells/mm 3 or 50 cells/mm 3 , respectively. The CD4 cell count can be expected to fall below these thresholds during chemotherapy, rendering patients susceptible to these infections [36] .
Anti-fungal prophylaxis or treatment with voriconazole and posaconazole, which inhibit CYP3A4, have unpredictable interactions with PIs [40] . In the majority of patients combining voriconazole with atazanavir and ritonavir, a reduction in exposure of both drugs is expected. However, in a small number without a functional CYP2C19 allele, voriconazole exposure increases more than 5-fold [42] . Co-administration of triazoles with PIs is therefore not recommended unless justified after careful risk/benefit assessment. If unavoidable, patients should be carefully monitored for voriconazole-associated adverse reactions and loss of either voriconazole or PI efficacy. The European labeling for atazanavir recommends determining a patient's CYP2C19 genotype if feasible [42] .
Granulocyte-Colony Stimulating Factor
In many settings, HIV-patients receiving chemotherapy are routinely given prophylactic hematopoietic growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), to prevent or limit neutropenia in anticipation of increased toxicity of chemotherapy with cART [36, 56] .
Other Medications
Numerous anti-emetics (e.g. domperidone), opioid analgesics and steroids also have significant DDIs with cART [57] and these should be individually checked prior to prescribing.
Clinical Monitoring and Dose Adjustment
Atazanavir causes unconjugated hyperbilirubinemia secondary to UGT-1A inhibition, and bilirubin alone is not a reliable guide for dose adjustment of chemotherapy agents such as docetaxel, doxorubicin, and etoposide in patients on this drug [4] .
Rilpivirine, dolutegravir and cobicistat may cause mild to moderate non-pathological increases in serum creatinine by reducing the secretion of creatinine through the proximal renal tubules. This does not reflect a reduction in the glomerular filtration rate (GFR) and should be carefully interpreted in the setting of potentially nephrotoxic chemotherapy drugs [58] . Several studies and meta-analyses have found that cystatin C (CysC) significantly outperformed serum creatinine for the monitoring of GFR in critically ill patients [59] .
Furthermore, in an analysis of 16 studies that directly compared the impact of CysC and of creatinine clearance on drug elimination, 13 found CysC to be superior [59] . These included studies of topotecan and carboplatin clearance, which correlated better with CysC than with creatinine clearance, and confirmed findings from a previous study in oncology patients [60] . With the caveat that CysC may be affected by high-dose corticosteroids, inflammation and hyperbilirubinemia [61] , it remains a useful additional measure of renal function in patients with HIV and malignancy.
Hematopoietic Stem Cell Transplantation
Numerous case reports and series have been published on autologous and allogeneic hematopoietic stem cell transplantation (HSCT) in HIV-infected patients [62] [63] [64] [65] , and HSCT has become a standard treatment option for HIV patients with hematological malignancies [36, 66] . The outcome of HSCTs improved significantly after the advent of cART and there is generally consensus that cART should be continued during high-dose chemotherapy for HSCT [66] .
The principals of avoiding and managing DDIs in HIV patients undergoing HSCT are identical to those outlined above. As with standard chemotherapy, TDF or TAF with emtricitabine and raltegravir would be the preferred cART to minimize drug interactions, but the same cautions apply. For example, co-administration of TDF and mycophenolate or TDF and ganciclovir or valganciclovir could increase the levels of both drugs due to competition for active tubular secretion, but this is not expected to be a problem with TAF [42] . Careful renal monitoring is mandatory if this drug combination is unavoidable.
A recent case series provides some evidence that the combination of TDF or TAF with emtricitabine and raltegravir is suitable for patients undergoing HSCT with high-dose chemotherapy and subsequent immunosuppression with nephrotoxic drugs [65] . The authors reported the successful treatment with cART during and after allogeneic HSCT in 5 patients. All 5 received TDF/emtricitabine, 4 in combination with raltegravir and 1 with efavirenz. There was no transplant-related mortality and the HIV viral load remained fully suppressed in all patients. 1 patient developed renal failure that resolved with hydration and substitution of TDF with abacavir [65] .
If the use of PIs is unavoidable, TDM of, among others, cyclosporine and mycophenolate is recommended as their levels may increase [42] .
No interactions are expected with monoclonal antibodies (mAbs), e.g. rituximab, as their elimination is similar to endogenous IgG and occurs primarily via proteolytic catabolism throughout the body [42] . Anti-thymocyte globulins (ATG) are antibodies against T cell markers including CD4, CCR5 and CXCR4. In a study of renal transplant patients, ATG caused a long-lasting reduction of CD4 cells in HIV patients receiving cART after renal transplant with the time to achieve a CD4 cell count of > 200 cells/ μl averaging 342 days despite maintaining effective cART [67] .
Of future interest outside of its role as ARV, maraviroc has shown promise in the prevention of graft-versus-host-disease (GVHD) after allogeneic HSCT in several preliminary studies [20] . The use of maraviroc for GVHD prevention is currently the subject of several clinical trials [68] .
Conclusion
Definitive clinical guidance on how to safely and effectively combine cART and anti-cancer agents is lacking and urgently needed. Several clinical studies addressing this increasingly important management challenge are currently ongoing through the AIDS Malignancy Consortium [68] .
The choice of cART for patients undergoing cancer treatment is highly individual and should be based on the clinical-and ARV history and on an understanding of the metabolism of the proposed drugs and their potential DDIs. Effective collaboration and meticulous monitoring by an oncologist, infectious diseases physician and pharmacist is essential. Despite the complexity, it is possible to effectively and safely treat both the malignancy and HIV and to achieve cancer outcomes approaching those in HIV-uninfected patients.
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